225 related articles for article (PubMed ID: 7620940)
1. Genetic polymorphism of cytochromes P450 1A1, 2D6 and 2E1: regulation and toxicological significance.
Rannug A; Alexandrie AK; Persson I; Ingelman-Sundberg M
J Occup Environ Med; 1995 Jan; 37(1):25-36. PubMed ID: 7620940
[TBL] [Abstract][Full Text] [Related]
2. Genetic polymorphism of cytochromes P450: interethnic differences and relationship to incidence of lung cancer.
Ingelman-Sundberg M; Johansson I; Persson I; Yue QY; Dahl ML; Bertilsson L; Sjöqvist F
Pharmacogenetics; 1992 Dec; 2(6):264-71. PubMed ID: 1306127
[TBL] [Abstract][Full Text] [Related]
3. Metabolic cytochrome P450 genotypes and assessment of individual susceptibility to lung cancer.
Hirvonen A; Husgafvel-Pursiainen K; Anttila S; Karjalainen A; Sorsa M; Vainio H
Pharmacogenetics; 1992 Dec; 2(6):259-63. PubMed ID: 1306126
[TBL] [Abstract][Full Text] [Related]
4. Metabolism of theophylline by cDNA-expressed human cytochromes P-450.
Ha HR; Chen J; Freiburghaus AU; Follath F
Br J Clin Pharmacol; 1995 Mar; 39(3):321-6. PubMed ID: 7619675
[TBL] [Abstract][Full Text] [Related]
5. Association between genetic polymorphisms of the cytochromes P-450 (1A1, 2D6, and 2E1) and the susceptibility to pancreatic cancer.
Lee HC; Yoon YB; Kim CY
Korean J Intern Med; 1997 Jun; 12(2):128-36. PubMed ID: 9439147
[TBL] [Abstract][Full Text] [Related]
6. Comparative cytochrome P450 -1A1, -2A6, -2B6, -2C, -2D6, -2E1, -3A5 and -4B1 expressions in human larynx tissue analysed at mRNA level.
Sarikaya D; Bilgen C; Kamataki T; Topcu Z
Biopharm Drug Dispos; 2006 Nov; 27(8):353-9. PubMed ID: 16894644
[TBL] [Abstract][Full Text] [Related]
7. Analysis of cytochrome P450 2E1 genetic polymorphisms in relation to human lung cancer.
Kato S; Shields PG; Caporaso NE; Sugimura H; Trivers GE; Tucker MA; Trump BF; Weston A; Harris CC
Cancer Epidemiol Biomarkers Prev; 1994 Sep; 3(6):515-8. PubMed ID: 8000304
[TBL] [Abstract][Full Text] [Related]
8. [Combined effects of genetic polymorphisms in cytochrome P450s and GSTM1 on lung cancer susceptibility].
Gu YF; Zhang ZD; Zhang SC; Zheng SH; Jia HY; Gu SX
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(43):3064-8. PubMed ID: 18261353
[TBL] [Abstract][Full Text] [Related]
9. CYP enzyme polymorphisms and susceptibility to HCV-related chronic liver disease and liver cancer.
Silvestri L; Sonzogni L; De Silvestri A; Gritti C; Foti L; Zavaglia C; Leveri M; Cividini A; Mondelli MU; Civardi E; Silini EM
Int J Cancer; 2003 Apr; 104(3):310-7. PubMed ID: 12569554
[TBL] [Abstract][Full Text] [Related]
10. Genetic factors in individual responses to environmental exposures.
Hirvonen A
J Occup Environ Med; 1995 Jan; 37(1):37-43. PubMed ID: 7620941
[TBL] [Abstract][Full Text] [Related]
11. Assessment of cancer susceptibility in humans by use of genetic polymorphisms in carcinogen metabolism.
Ikawa S; Uematsu F; Watanabe K; Kimpara T; Osada M; Hossain A; Sagami I; Kikuchi H; Watanabe M
Pharmacogenetics; 1995; 5 Spec No():S154-60. PubMed ID: 7581487
[TBL] [Abstract][Full Text] [Related]
12. Effects of ALDH2, CYP1A1, and CYP2E1 genetic polymorphisms and smoking and drinking habits on toluene metabolism in humans.
Kawamoto T; Koga M; Murata K; Matsuda S; Kodama Y
Toxicol Appl Pharmacol; 1995 Aug; 133(2):295-304. PubMed ID: 7645026
[TBL] [Abstract][Full Text] [Related]
13. Human AH locus polymorphism and cancer: inducibility of CYP1A1 and other genes by combustion products and dioxin.
Nebert DW; Petersen DD; Puga A
Pharmacogenetics; 1991 Nov; 1(2):68-78. PubMed ID: 1844873
[TBL] [Abstract][Full Text] [Related]
14. Evidence-based prevention (EBP): approach to lung cancer prevention based on cytochrome 1A1 and cytochrome 2E1 polymorphism.
Oyama T; Matsumoto A; Isse T; Kim YD; Ozaki S; Osaki T; Sugio K; Yasumoto K; Kawamoto T
Anticancer Res; 2003; 23(2C):1731-7. PubMed ID: 12820449
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in understanding the molecular basis of polymorphisms in genes encoding cytochrome P450 enzymes.
Daly AK; Fairbrother KS; Smart J
Toxicol Lett; 1998 Dec; 102-103():143-7. PubMed ID: 10022246
[TBL] [Abstract][Full Text] [Related]
16. Debrisoquin oxidation genotype and susceptibility to lung cancer.
Agúndez JA; Martínez C; Ladero JM; Ledesma MC; Ramos JM; Martín R; Rodriguez A; Jara C; Benítez J
Clin Pharmacol Ther; 1994 Jan; 55(1):10-4. PubMed ID: 8299311
[TBL] [Abstract][Full Text] [Related]
17. CYP1A1 and CYP2E1 polymorphism and lung cancer, case-control study in Rio de Janeiro, Brazil.
Sugimura H; Hamada GS; Suzuki I; Iwase T; Kiyokawa E; Kino I; Tsugane S
Pharmacogenetics; 1995; 5 Spec No():S145-8. PubMed ID: 7581485
[TBL] [Abstract][Full Text] [Related]
18. Cytochrome P450 expression (CYP) in non-small cell lung cancer.
Oyama T; Sugio K; Uramoto H; Kawamoto T; Kagawa N; Nadaf S; Carbone D; Yasumoto K
Front Biosci; 2007 Jan; 12():2299-308. PubMed ID: 17127240
[TBL] [Abstract][Full Text] [Related]
19. Cytochromes P450 and cancer.
Kaminsky LS; Spivack SD
Mol Aspects Med; 1999; 20(1-2):70-84, 137. PubMed ID: 10575653
[No Abstract] [Full Text] [Related]
20. Relationship between genetic polymorphisms of drug-metabolizing enzymes (CYP1A1, CYP2E1, GSTM1, and NAT2), drinking habits, histological subtypes, and p53 gene point mutations in Japanese patients with gastric cancer.
Suzuki S; Muroishi Y; Nakanishi I; Oda Y
J Gastroenterol; 2004; 39(3):220-30. PubMed ID: 15064998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
